PHASE-II TRIAL OF VINDESINE IN THE TREATMENT OF LYMPHOMAS, BREAST-CANCER, AND OTHER SOLID TUMORS
- 1 January 1980
- journal article
- research article
- Vol. 64 (8-9) , 1001-1003
Abstract
A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients with breast cancer, non-Hodgkin''s lymphoma and other tumors. There were 2 partial responses in 11 patients with breast cancer (18%) and 5 partial responses and 1 complete response in 11 patients with non-Hodgkin''s lymphoma (40%). Other responses were seen in small cell carcinoma of the lung, ovarian carcinoma and Hodgkin''s disease. Prior vinca exposure did not adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. A high incidence of local tissue reactions at the injection site (27%) were reduced by a careful administration technique. Vindesine should be studied further in combination with other agents.This publication has 2 references indexed in Scilit:
- PHASE-II CLINICAL-TRIAL WITH VINDESINE FOR REMISSION INDUCTION IN ACUTE-LEUKEMIA, BLASTIC CRISIS OF CHRONIC MYELOID-LEUKEMIA, LYMPHOSARCOMA, AND HODGKINS-DISEASE - ABSENCE OF CROSS-RESISTANCE WITH VINCRISTINE1978
- VINDESINE - PHASE-II STUDY IN TREATMENT OF BREAST CARCINOMA, MALIGNANT-MELANOMA, AND OTHER TUMORS1978